The content of this website has been produced in line with the IBRANCE® Summary of Product Characteristics for Great Britain. IBRANCE® (palbociclib) Prescribing Information for Great Britain click here. IBRANCE® (palbociclib) Prescribing Information for Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.
Adapting Breast Cancer Care during COVID-19 pandemic
Pfizer is committed to supporting its NHS colleagues during the COVID-19 Pandemic.
NHS England has released guidance on the management of Cancer Patients at this difficult time.1 This guidance provides the following recommendations which we believe we can provide assistance with:
- Consider dispensing longer periods of oral medications if at all possible, to minimise patient exposure
- Seek alternative methods to monitor and review patients on systemic therapies.
As such, we would like to bring to your attention the availability of our 3-month packaging for IBRANCE®▼ (palbociclib).
The 3-month packaging is available in addition to the 1-month packaging and can be ordered via the same process.
The following table provides some further useful information when ordering:
PRODUCT CODE |
PIP |
|---|---|
IBRANCE® TAB 125 mg x 63 |
416-5189 |
IBRANCE® TAB 100 mg x 63 |
416-5171 |
IBRANCE® TAB 75 mg x 63 |
416-5163 |
We can confirm that we are not making any changes to the current Patient Access scheme.
In line with our IBRANCE® Summary of Product Characteristics, for Patients who experience a maximum of Grade 1 or 2 Neutropenia in the first 6 Cycles, complete blood counts for subsequent cycles should be monitored every 3 months, prior to the beginning of a cycle and as clinically indicated.2
These patients may benefit from the 3-month packaging.
Should you require any help or assistance with necessary coding for the 3-month packaging, please contact our Customer Contact Centre on 0345 608 8866. Alternatively, you can contact your local Pfizer representative.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
- NHS England. Clinical guide for the management of noncoronavirus patients requiring acute treatment: Cancer. Publications approval reference: 001559. Available at: https://www.nice.org.uk/Media/Default/About/COVID-19/Specialty-guides/cancer-and-COVID-19.pdf (accessed May 2021)
- IBRANCE® Summary of Product Characteristics for Great Britain click here. IBRANCE® Summary of Product Characteristics for Northern Ireland click here.
Resources
IBRANCE® Resources Patient Resources Video Resources
Indication
- IBRANCE® is indicated for the treatment of HR+/HER2- locally advanced or metastatic breast cancer:
- In combination with an aromatase inhibitor; or
- In combination with fulvestrant in women who have received prior ET
In pre- or perimenopausal women, the ET should be combined with a LHRH agonist
For UK Healthcare Professionals*
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020
No